novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Heart Failure and Chronic Kidney Disease. Challenges in RAASi optimization: Hyperkalemia Management

22 Dezembro 2020

Statins and combination therapies. How they are changing the modern cardiovascular medicine

17 Dezembro 2020
0

Cardiac amyloidosis. Diagnosis and management

22 Dezembro 2020
0

-->